Simon Jäger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Simon Jäger has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Elke Schaeffeler
Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany
11 shared publications - Matthias Schwab
Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany
11 shared publications - Roman Tremmel
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany
11 shared publications - Svitlana Igel
Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany
11 shared publications Andrea Stefek
10 shared publications- Andreas Gerteis
Department of Gynecology and Obstetrics, Robert Bosch Hospital, Stuttgart, Germany
10 shared publications
Latest Publications
- Open Access
Digital Assessment of Real-World Physical Activity in Pulmonary Hypertension: A Systematic Review and Meta-Analysis
Background: The assessment of daily-life physical activity (DLPA) using wearables in patients with pulmonary hypertension (PH) can provide information on real-world function, potentially enhancing the evaluation of disease progression. Research Question: What is the existing evidence on sensor-based DLPA assessment in patients with PH and its quality? Study Design and Methods: We searched MEDLINE and Embase from inception to January 13, 2026, extracting data on devices, DLPA outcomes, and associations with clinical outcomes. We obtained pooled estimates through random-effects models and assessed evidence quality using a customized tool. Results: We identified 33 studies (29 adult, 4 pediatric) including 1,257 patients mainly with pulmonary arterial hypertension (PAH), followed by chronic thromboembolic PH (CTEPH), and only rarely with PH due to lung diseases and/or hypoxia. Participants were predominantly female, WHO functional class II-III. Most studies investigated step count and time spent in different physical activity levels, but showed substantial heterogeneity in devices and their utilization. The meta-estimate was 4,811 daily steps. A moderate positive correlation was found between daily step count and six-minute walking distance (6MWD) (r=0.59, 95%CI 0.47-0.69); a weak positive correlation was found between time spent in moderate-to-vigorous physical activity and 6MWD (r=0.38; 95% CI 0.26-0.49). Inconsistent wear-time definition, non-wear reporting and temporal misalignment of DLPA may compromise validity and comparability. Interpretation: Wearable-based DLPA assessment in PH is feasible, though high-quality evidence remains scarce. Future research should standardize procedures, terminology, and reporting of DLPA outcomes. Concordance with established measures such as the 6MWD, and their ability to predict clinical outcomes and disease progression need to be demonstrated.
Open AccessDigital Assessment of Real-World Physical Activity in Pulmonary Hypertension: A Systematic Review and Meta-Analysis
Background: The assessment of daily-life physical activity (DLPA) using wearables in patients with pulmonary hypertension (PH) can provide information on real-world function, potentially enhancing the evaluation of disease progression. Research Question: What is the existing evidence on sensor-based DLPA assessment in patients with PH and its quality? Study Design and Methods: We searched MEDLINE and Embase from inception to January 13, 2026, extracting data on devices, DLPA outcomes, and associations with clinical outcomes. We obtained pooled estimates through random-effects models and assessed evidence quality using a customized tool. Results: We identified 33 studies (29 adult, 4 pediatric) including 1,257 patients mainly with pulmonary arterial hypertension (PAH), followed by chronic thromboembolic PH (CTEPH), and only rarely with PH due to lung diseases and/or hypoxia. Participants were predominantly female, WHO functional class II-III. Most studies investigated step count and time spent in different physical activity levels, but showed substantial heterogeneity in devices and their utilization. The meta-estimate was 4,811 daily steps. A moderate positive correlation was found between daily step count and six-minute walking distance (6MWD) (r=0.59, 95%CI 0.47-0.69); a weak positive correlation was found between time spent in moderate-to-vigorous physical activity and 6MWD (r=0.38; 95% CI 0.26-0.49). Inconsistent wear-time definition, non-wear reporting and temporal misalignment of DLPA may compromise validity and comparability. Interpretation: Wearable-based DLPA assessment in PH is feasible, though high-quality evidence remains scarce. Future research should standardize procedures, terminology, and reporting of DLPA outcomes. Concordance with established measures such as the 6MWD, and their ability to predict clinical outcomes and disease progression need to be demonstrated.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Inter- and intra-assay variability
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Inter- and intra-assay variability
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Suppl Fig S2: Concentration ratio (E)-endoxifen to (Z)-endoxifen
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Suppl Fig S2: Concentration ratio (E)-endoxifen to (Z)-endoxifen
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Inclusion and exclusion criteria
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Inclusion and exclusion criteria
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Endpoint analysis in PP-population
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Endpoint analysis in PP-population
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Representativeness of study participants
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Representativeness of study participants
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Suppl Fig. S1: Concentration time course of tamoxifen, N-desmentyl tamoxifen, (Z)-4-hydroxy tamoxifen, and (Z)-endoxifen
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Suppl Fig. S1: Concentration time course of tamoxifen, N-desmentyl tamoxifen, (Z)-4-hydroxy tamoxifen, and (Z)-endoxifen